Articles by Eric Langer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Eric Langer

Eric Langer


is president and managing partner of BioPlan Associates.

Articles
Cost Is No Longer the Driving Force for Outsourcing
June 29, 2014

With budgets growing, clients see CMOs' costs as less crucial and consider other factors.

Outsourcing No Longer Just for Cost-Cutting
June 2, 2014

With budgets growing, clients see CMOs' costs as less crucial.

Outsourcing Remains Strong In Traditional Areas
May 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Biopharma Outsourcing Activities Update
April 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Top 10 Outsourcing Trends in Biopharmaceutical Manufacturing
February 28, 2014

In biopharmaceutical manufacturing, outsourcing and off-shoring have migrated into much more high-value areas.

Outsourcing Trends in Biopharmaceutical Manufacturing
February 1, 2014

A changing biopharmaceutical industry is going beyond typically outsourced activities and is using CMOs for more challenging processes. Review the top 10 outsourcing trends.

Bioprocessing Advances in Vaccine Manufacture
September 4, 2013

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

Making the Best of a Bad CMO-Client Relationship
September 1, 2013

A CMO perspective on the CMO-client partnership.

What Happened to Outsourcing in Asia?
August 7, 2013

The industry may not be ready for India and China as regulatory issues emerge.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here